A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

Bo Tsang Huang; Wei Yun Lai; Yi Chung Chang; Jen Wei Wang; Shauh Der Yeh; Emily Pei Ying Lin; Pan Chyr Yang

doi:10.1016/j.omtn.2017.08.006

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

Bo Tsang Huang
, Wei Yun Lai
, Yi Chung Chang
, Jen Wei Wang
, Shauh Der Yeh
, Emily Pei Ying Lin
, Pan Chyr Yang

Research output: Contribution to journal › Article › peer-review

71 Citations (Scopus)

Abstract

The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.

Original language	English
Pages (from-to)	520-528
Number of pages	9
Journal	Molecular Therapy Nucleic Acids
Volume	8
DOIs	https://doi.org/10.1016/j.omtn.2017.08.006
Publication status	Published - Sept 15 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CTLA-4
aptamer
cancer
immunotherapy

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.omtn.2017.08.006

Cite this

@article{2724dc77bf6f4205a183749f0478367e,

title = "A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect",

abstract = "The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.",

keywords = "CTLA-4, aptamer, cancer, immunotherapy",

author = "Huang, \{Bo Tsang\} and Lai, \{Wei Yun\} and Chang, \{Yi Chung\} and Wang, \{Jen Wei\} and Yeh, \{Shauh Der\} and Lin, \{Emily Pei Ying\} and Yang, \{Pan Chyr\}",

note = "Funding Information: We dedicate this work to Dr. Konan Peck, a respected researcher in the fields of high-throughput biotechnology, biophysics, and cancer genomics. Shortly after initiating this project, Dr. Peck unfortunately succumbed to a rapidly progressing cancer. It is our fervent hope that the research platform established by Dr. Peck will result in the development of new diagnostic and therapeutic options that benefit cancer patients. We also thank the National Center for Genome Medicine for the technical and bioinformatics support. This project was supported by grants from the National Science Council ( NSC99-2320-B-001-012-MY3 and MOST104-2314-B-002-228-MY3 ). ",

year = "2017",

month = sep,

day = "15",

doi = "10.1016/j.omtn.2017.08.006",

language = "English",

volume = "8",

pages = "520--528",

journal = "Molecular Therapy Nucleic Acids",

issn = "2162-2531",

publisher = "Cell Press",

}

TY - JOUR

T1 - A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

AU - Huang, Bo Tsang

AU - Lai, Wei Yun

AU - Chang, Yi Chung

AU - Wang, Jen Wei

AU - Yeh, Shauh Der

AU - Lin, Emily Pei Ying

AU - Yang, Pan Chyr

N1 - Funding Information: We dedicate this work to Dr. Konan Peck, a respected researcher in the fields of high-throughput biotechnology, biophysics, and cancer genomics. Shortly after initiating this project, Dr. Peck unfortunately succumbed to a rapidly progressing cancer. It is our fervent hope that the research platform established by Dr. Peck will result in the development of new diagnostic and therapeutic options that benefit cancer patients. We also thank the National Center for Genome Medicine for the technical and bioinformatics support. This project was supported by grants from the National Science Council ( NSC99-2320-B-001-012-MY3 and MOST104-2314-B-002-228-MY3 ).

PY - 2017/9/15

Y1 - 2017/9/15

N2 - The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.

AB - The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.

KW - CTLA-4

KW - aptamer

KW - cancer

KW - immunotherapy

UR - https://www.scopus.com/pages/publications/85029349672

UR - https://www.scopus.com/pages/publications/85029349672#tab=citedBy

U2 - 10.1016/j.omtn.2017.08.006

DO - 10.1016/j.omtn.2017.08.006

M3 - Article

AN - SCOPUS:85029349672

SN - 2162-2531

VL - 8

SP - 520

EP - 528

JO - Molecular Therapy Nucleic Acids

JF - Molecular Therapy Nucleic Acids

ER -

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this